Annovis Bio (ANVS) Fundamental Analysis: Revenue, Earnings & Valuation

5.28 / 10

Netural

Comprehensive analysis: balanced fundamentals (5.3/10). Positive dimensions: Interest coverage ratio (EBIT / Interest expense) (%) and PB-ROE, but headwinds are noted in Quick ratio and Asset-MV. Resulting position: balanced.

Analysis Checks(7/10)

Revenue-MV

Value-0.18

Score3/3

Weight39.67%

1M Return8.82%

Total operating revenue (YoY growth rate %)

Value142.02

Score2/3

Weight1.19%

1M Return0.35%

Quick ratio

Value2.34

Score1/3

Weight-2.92%

1M Return-0.93%

PB-ROE

Value2.14

Score2/3

Weight28.15%

1M Return6.67%

Income tax / Total profit (%)

Value19.90

Score0/3

Weight-4.57%

1M Return-1.49%

Long-term debt to working capital ratio (%)

Value0.03

Score3/3

Weight5.94%

1M Return1.83%

Interest coverage ratio (EBIT / Interest expense) (%)

Value39.04

Score2/3

Weight-2.49%

1M Return-0.77%

Cost of sales ratio (%)

Value71.87

Score2/3

Weight-1.89%

1M Return-0.61%

Asset-MV

Value-0.72

Score1/3

Weight27.82%

1M Return6.94%

Current ratio

Value5.80

Score3/3

Weight9.11%

1M Return2.58%

Is ANVS undervalued or overvalued?

ANVS scores 5.28/10 on fundamentals and holds a Fair valuation at present. Backed by its -220.61% ROE, 0.00% net margin, -2.24 P/E ratio, 3.84 P/B ratio, and 30.69% earnings growth, these metrics solidify its Netural investment rating.